PIRS – pieris pharmaceuticals, inc. (US:NASDAQ)

News

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com